Konstantinos Papamichail, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Monitoring | 38 | 2023 | 961 | 9.940 |
Why?
|
Inflammatory Bowel Diseases | 53 | 2023 | 2397 | 9.500 |
Why?
|
Gastrointestinal Agents | 32 | 2023 | 494 | 8.400 |
Why?
|
Crohn Disease | 38 | 2023 | 2299 | 6.980 |
Why?
|
Tumor Necrosis Factor-alpha | 31 | 2023 | 4400 | 3.890 |
Why?
|
Biological Products | 14 | 2023 | 850 | 3.740 |
Why?
|
Colitis, Ulcerative | 20 | 2023 | 1899 | 3.320 |
Why?
|
Azathioprine | 8 | 2022 | 355 | 2.010 |
Why?
|
Remission Induction | 16 | 2023 | 2378 | 1.770 |
Why?
|
Immunosuppressive Agents | 13 | 2022 | 4143 | 1.370 |
Why?
|
Mesalamine | 4 | 2018 | 135 | 1.250 |
Why?
|
Helicobacter pylori | 3 | 2019 | 379 | 1.210 |
Why?
|
Helicobacter Infections | 3 | 2019 | 384 | 1.200 |
Why?
|
Tuberculin Test | 2 | 2015 | 211 | 1.000 |
Why?
|
Leukocyte L1 Antigen Complex | 2 | 2015 | 88 | 0.990 |
Why?
|
Antibodies, Monoclonal | 17 | 2022 | 9259 | 0.950 |
Why?
|
Anti-Inflammatory Agents | 9 | 2020 | 1777 | 0.940 |
Why?
|
Standard of Care | 4 | 2022 | 563 | 0.880 |
Why?
|
Latent Tuberculosis | 2 | 2015 | 223 | 0.860 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 6 | 2018 | 2277 | 0.850 |
Why?
|
Colonoscopy | 9 | 2020 | 1363 | 0.820 |
Why?
|
Heat-Shock Response | 4 | 2012 | 165 | 0.810 |
Why?
|
Immunologic Factors | 5 | 2022 | 1571 | 0.790 |
Why?
|
Serum | 3 | 2017 | 211 | 0.780 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2019 | 435 | 0.770 |
Why?
|
Intestinal Fistula | 1 | 2021 | 140 | 0.740 |
Why?
|
Capsule Endoscopy | 1 | 2021 | 125 | 0.720 |
Why?
|
Saccharomyces cerevisiae | 6 | 2019 | 2748 | 0.700 |
Why?
|
Calculi | 1 | 2019 | 46 | 0.680 |
Why?
|
Drug Tolerance | 2 | 2018 | 376 | 0.660 |
Why?
|
Proton-Translocating ATPases | 1 | 2019 | 116 | 0.660 |
Why?
|
Rectal Fistula | 1 | 2017 | 73 | 0.590 |
Why?
|
Thyroxine | 2 | 2019 | 666 | 0.580 |
Why?
|
Humans | 111 | 2023 | 739398 | 0.570 |
Why?
|
Arthritis, Psoriatic | 1 | 2019 | 212 | 0.560 |
Why?
|
Colitis | 2 | 2022 | 1146 | 0.550 |
Why?
|
Intestinal Mucosa | 6 | 2021 | 3036 | 0.530 |
Why?
|
Colectomy | 3 | 2017 | 681 | 0.510 |
Why?
|
Osteoporosis | 3 | 2019 | 1576 | 0.480 |
Why?
|
Saccharomyces cerevisiae Proteins | 4 | 2019 | 1884 | 0.440 |
Why?
|
Wound Healing | 4 | 2021 | 2768 | 0.440 |
Why?
|
Cyclosporine | 2 | 2017 | 781 | 0.430 |
Why?
|
Antibodies | 2 | 2019 | 2450 | 0.430 |
Why?
|
Histamine Antagonists | 1 | 2012 | 94 | 0.430 |
Why?
|
Cholangitis | 2 | 2018 | 108 | 0.420 |
Why?
|
Granular Cell Tumor | 1 | 2012 | 52 | 0.420 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2020 | 10945 | 0.410 |
Why?
|
Treatment Failure | 4 | 2019 | 2614 | 0.410 |
Why?
|
Recurrence | 7 | 2023 | 8307 | 0.390 |
Why?
|
Feces | 2 | 2015 | 1389 | 0.390 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1066 | 0.380 |
Why?
|
Colon | 2 | 2015 | 1771 | 0.380 |
Why?
|
Mitogens | 1 | 2010 | 232 | 0.370 |
Why?
|
Treatment Outcome | 22 | 2022 | 62693 | 0.370 |
Why?
|
Thyroid Diseases | 2 | 2010 | 378 | 0.360 |
Why?
|
Salvage Therapy | 2 | 2017 | 1269 | 0.340 |
Why?
|
Necrosis | 2 | 2023 | 1643 | 0.330 |
Why?
|
Tumor Necrosis Factors | 2 | 2019 | 109 | 0.320 |
Why?
|
Adult | 36 | 2022 | 213394 | 0.320 |
Why?
|
Peptides, Cyclic | 1 | 2010 | 400 | 0.310 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 973 | 0.300 |
Why?
|
Young Adult | 21 | 2022 | 56255 | 0.300 |
Why?
|
Delphi Technique | 2 | 2021 | 770 | 0.300 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 3863 | 0.300 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 319 | 0.300 |
Why?
|
Endocrine System Diseases | 1 | 2009 | 248 | 0.290 |
Why?
|
Drug Administration Schedule | 6 | 2018 | 4935 | 0.290 |
Why?
|
Retrospective Studies | 22 | 2023 | 76631 | 0.280 |
Why?
|
Fever of Unknown Origin | 1 | 2006 | 93 | 0.280 |
Why?
|
Middle Aged | 38 | 2022 | 212863 | 0.270 |
Why?
|
Thyrotropin | 1 | 2009 | 849 | 0.260 |
Why?
|
Arthritis, Rheumatoid | 2 | 2019 | 3689 | 0.260 |
Why?
|
Bone Remodeling | 1 | 2009 | 575 | 0.260 |
Why?
|
Female | 45 | 2021 | 378853 | 0.260 |
Why?
|
Male | 41 | 2023 | 349022 | 0.250 |
Why?
|
Arthritis | 1 | 2010 | 657 | 0.250 |
Why?
|
Thyroidectomy | 1 | 2009 | 876 | 0.230 |
Why?
|
Autoantibodies | 2 | 2021 | 2020 | 0.230 |
Why?
|
Integrins | 2 | 2019 | 845 | 0.230 |
Why?
|
Soft Tissue Neoplasms | 1 | 2012 | 1359 | 0.220 |
Why?
|
Lymphocytes | 1 | 2010 | 2612 | 0.210 |
Why?
|
Methotrexate | 4 | 2022 | 1711 | 0.210 |
Why?
|
Withholding Treatment | 2 | 2018 | 596 | 0.210 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2116 | 0.190 |
Why?
|
Adolescent | 14 | 2022 | 85405 | 0.180 |
Why?
|
Histamine | 2 | 2014 | 503 | 0.180 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2020 | 370 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6516 | 0.180 |
Why?
|
Adaptation, Physiological | 4 | 2012 | 1310 | 0.170 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5522 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 163 | 0.170 |
Why?
|
Colorectal Neoplasms | 4 | 2023 | 6726 | 0.170 |
Why?
|
Bone Density Conservation Agents | 2 | 2018 | 771 | 0.170 |
Why?
|
Pharmacogenetics | 1 | 2023 | 679 | 0.170 |
Why?
|
Prospective Studies | 10 | 2023 | 53037 | 0.170 |
Why?
|
Belgium | 2 | 2017 | 103 | 0.160 |
Why?
|
Drug Substitution | 1 | 2021 | 283 | 0.160 |
Why?
|
Sentinel Surveillance | 1 | 2020 | 291 | 0.160 |
Why?
|
Hepatitis B Core Antigens | 1 | 2018 | 92 | 0.160 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2016 | 857 | 0.160 |
Why?
|
Intra-Abdominal Fat | 1 | 2023 | 590 | 0.160 |
Why?
|
Hepatitis B Antibodies | 1 | 2018 | 158 | 0.150 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3844 | 0.150 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1583 | 0.150 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2018 | 305 | 0.150 |
Why?
|
Causality | 1 | 2023 | 1262 | 0.140 |
Why?
|
Virus Activation | 1 | 2018 | 319 | 0.140 |
Why?
|
Postoperative Hemorrhage | 1 | 2019 | 410 | 0.140 |
Why?
|
Cycloheximide | 3 | 2012 | 347 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 9812 | 0.130 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 143 | 0.130 |
Why?
|
Consensus | 2 | 2021 | 2913 | 0.130 |
Why?
|
Hepatitis B virus | 1 | 2018 | 510 | 0.120 |
Why?
|
Follow-Up Studies | 4 | 2018 | 38942 | 0.120 |
Why?
|
Comorbidity | 3 | 2019 | 10362 | 0.120 |
Why?
|
Prognosis | 5 | 2023 | 28901 | 0.120 |
Why?
|
Ranitidine | 1 | 2014 | 34 | 0.120 |
Why?
|
Drug Therapy, Combination | 5 | 2017 | 6478 | 0.120 |
Why?
|
Cytodiagnosis | 1 | 2017 | 433 | 0.120 |
Why?
|
C-Reactive Protein | 3 | 2021 | 3752 | 0.120 |
Why?
|
Clostridium Infections | 1 | 2020 | 549 | 0.120 |
Why?
|
Abdominal Pain | 1 | 2019 | 1053 | 0.110 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 2012 | 403 | 0.110 |
Why?
|
Informed Consent | 1 | 2019 | 988 | 0.110 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 7274 | 0.110 |
Why?
|
Histamine H2 Antagonists | 1 | 2014 | 165 | 0.110 |
Why?
|
Forecasting | 1 | 2022 | 2952 | 0.110 |
Why?
|
Ileum | 1 | 2015 | 563 | 0.110 |
Why?
|
Gastritis | 1 | 2014 | 192 | 0.110 |
Why?
|
Risk Factors | 10 | 2019 | 71974 | 0.100 |
Why?
|
Pilot Projects | 3 | 2015 | 8275 | 0.100 |
Why?
|
Lymphoma | 1 | 2021 | 1873 | 0.100 |
Why?
|
Documentation | 1 | 2017 | 861 | 0.100 |
Why?
|
Microbial Viability | 1 | 2012 | 236 | 0.100 |
Why?
|
Cohort Studies | 7 | 2020 | 40389 | 0.100 |
Why?
|
Osteogenesis | 1 | 2018 | 1292 | 0.100 |
Why?
|
Heat-Shock Proteins | 2 | 2012 | 825 | 0.100 |
Why?
|
Safety | 1 | 2016 | 1186 | 0.100 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 808 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 2016 | 1339 | 0.100 |
Why?
|
Guideline Adherence | 2 | 2020 | 2261 | 0.100 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2014 | 386 | 0.100 |
Why?
|
Hospitalization | 3 | 2019 | 10208 | 0.100 |
Why?
|
Lumbosacral Region | 1 | 2012 | 309 | 0.090 |
Why?
|
ROC Curve | 1 | 2018 | 3526 | 0.090 |
Why?
|
Rheumatic Diseases | 1 | 2017 | 590 | 0.090 |
Why?
|
Secondary Prevention | 2 | 2018 | 1516 | 0.090 |
Why?
|
Carcinoma, Medullary | 1 | 2010 | 122 | 0.090 |
Why?
|
Aged, 80 and over | 8 | 2022 | 57650 | 0.090 |
Why?
|
Risk Assessment | 3 | 2023 | 23294 | 0.090 |
Why?
|
Child | 3 | 2023 | 77033 | 0.090 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3051 | 0.090 |
Why?
|
Time Factors | 7 | 2018 | 40050 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2275 | 0.090 |
Why?
|
Diphosphonates | 1 | 2014 | 624 | 0.090 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7626 | 0.080 |
Why?
|
Calcitonin | 1 | 2010 | 336 | 0.080 |
Why?
|
Aged | 13 | 2022 | 162698 | 0.080 |
Why?
|
Seroepidemiologic Studies | 1 | 2010 | 401 | 0.080 |
Why?
|
Tuberculosis, Cardiovascular | 1 | 2008 | 9 | 0.080 |
Why?
|
Premedication | 1 | 2009 | 257 | 0.080 |
Why?
|
Cell Survival | 1 | 2019 | 5877 | 0.080 |
Why?
|
Immune System | 1 | 2014 | 801 | 0.080 |
Why?
|
Hot Temperature | 3 | 2006 | 1358 | 0.080 |
Why?
|
Protective Agents | 1 | 2009 | 156 | 0.080 |
Why?
|
Phosphorus | 1 | 2009 | 338 | 0.080 |
Why?
|
Protein Biosynthesis | 2 | 2012 | 2131 | 0.080 |
Why?
|
Hyperparathyroidism | 1 | 2009 | 339 | 0.080 |
Why?
|
Imidazoles | 1 | 2014 | 1207 | 0.080 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 459 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 3908 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14740 | 0.080 |
Why?
|
Drug Costs | 1 | 2015 | 1115 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2021 | 11985 | 0.070 |
Why?
|
Cholagogues and Choleretics | 1 | 2006 | 32 | 0.070 |
Why?
|
Ursodeoxycholic Acid | 1 | 2006 | 72 | 0.070 |
Why?
|
Adenoma | 1 | 2017 | 2167 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7298 | 0.070 |
Why?
|
Anaphylaxis | 1 | 2014 | 747 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5462 | 0.070 |
Why?
|
gamma-Glutamyltransferase | 1 | 2006 | 133 | 0.070 |
Why?
|
Radiography | 1 | 2017 | 6998 | 0.070 |
Why?
|
Collagen Type I | 1 | 2009 | 577 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2881 | 0.070 |
Why?
|
Pericardial Effusion | 1 | 2008 | 241 | 0.070 |
Why?
|
Endoscopy | 1 | 2015 | 1762 | 0.070 |
Why?
|
Hydrocortisone | 2 | 2014 | 1809 | 0.070 |
Why?
|
Inflammation Mediators | 1 | 2014 | 1890 | 0.070 |
Why?
|
Education, Medical | 1 | 2017 | 1712 | 0.070 |
Why?
|
Ligands | 1 | 2012 | 3311 | 0.070 |
Why?
|
Postoperative Care | 1 | 2012 | 1477 | 0.070 |
Why?
|
Benzoquinones | 1 | 2006 | 201 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2015 | 1957 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2017 | 2971 | 0.060 |
Why?
|
Drug Hypersensitivity | 1 | 2014 | 889 | 0.060 |
Why?
|
Methylprednisolone | 1 | 2006 | 388 | 0.060 |
Why?
|
Lymph Nodes | 2 | 2021 | 3454 | 0.060 |
Why?
|
Prednisolone | 1 | 2006 | 332 | 0.060 |
Why?
|
Camptothecin | 2 | 2006 | 570 | 0.060 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 970 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1832 | 0.060 |
Why?
|
Influenza Vaccines | 1 | 2011 | 740 | 0.060 |
Why?
|
Hypothyroidism | 1 | 2009 | 659 | 0.060 |
Why?
|
Lactams, Macrocyclic | 1 | 2006 | 320 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2448 | 0.060 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 779 | 0.060 |
Why?
|
Polysaccharides | 1 | 2010 | 1050 | 0.060 |
Why?
|
Alkaline Phosphatase | 1 | 2006 | 864 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2009 | 1799 | 0.050 |
Why?
|
Piperazines | 1 | 2012 | 2480 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15036 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 623 | 0.050 |
Why?
|
Dyslipidemias | 1 | 2009 | 851 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 3101 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11410 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12328 | 0.050 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2022 | 708 | 0.050 |
Why?
|
Influenza, Human | 1 | 2011 | 1476 | 0.050 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1329 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2019 | 15194 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2017 | 4189 | 0.050 |
Why?
|
Laxatives | 1 | 2020 | 87 | 0.040 |
Why?
|
Saccharomyces | 1 | 2000 | 66 | 0.040 |
Why?
|
Molybdenum | 1 | 1999 | 46 | 0.040 |
Why?
|
Immunotherapy | 1 | 2015 | 4391 | 0.040 |
Why?
|
Mass Screening | 1 | 2015 | 5265 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6610 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4539 | 0.040 |
Why?
|
Thyroid Neoplasms | 2 | 2010 | 2267 | 0.040 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2019 | 301 | 0.040 |
Why?
|
Estradiol | 1 | 2006 | 2021 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 1373 | 0.040 |
Why?
|
Academic Medical Centers | 2 | 2019 | 2749 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15153 | 0.040 |
Why?
|
Peptides | 1 | 2009 | 4395 | 0.040 |
Why?
|
Private Practice | 1 | 2017 | 154 | 0.040 |
Why?
|
Retreatment | 1 | 2018 | 603 | 0.030 |
Why?
|
Calcium | 1 | 2009 | 5742 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1038 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2015 | 68 | 0.030 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2019 | 450 | 0.030 |
Why?
|
Colonic Polyps | 1 | 2019 | 543 | 0.030 |
Why?
|
Acute-Phase Reaction | 1 | 2014 | 92 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 29002 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3263 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 423 | 0.030 |
Why?
|
Complement C1r | 1 | 2013 | 5 | 0.030 |
Why?
|
beta 2-Glycoprotein I | 1 | 2013 | 27 | 0.030 |
Why?
|
Resistin | 1 | 2014 | 170 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1689 | 0.030 |
Why?
|
Plasminogen | 1 | 2013 | 152 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2017 | 719 | 0.030 |
Why?
|
Clusterin | 1 | 2013 | 72 | 0.030 |
Why?
|
Complement C4b | 1 | 2013 | 133 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13402 | 0.030 |
Why?
|
Vitamin D-Binding Protein | 1 | 2013 | 130 | 0.030 |
Why?
|
Medical Records | 1 | 2017 | 1413 | 0.030 |
Why?
|
Up-Regulation | 2 | 2013 | 4205 | 0.030 |
Why?
|
Transferrin | 1 | 2013 | 295 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2013 | 281 | 0.030 |
Why?
|
Cross Reactions | 1 | 2014 | 840 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2015 | 983 | 0.030 |
Why?
|
United States | 1 | 2019 | 69573 | 0.020 |
Why?
|
Disease Progression | 2 | 2023 | 13237 | 0.020 |
Why?
|
DNA, Viral | 1 | 2018 | 2223 | 0.020 |
Why?
|
Fellowships and Scholarships | 1 | 2019 | 1058 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1655 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5702 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 24714 | 0.020 |
Why?
|
Prescription Drugs | 1 | 2017 | 594 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 35326 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2575 | 0.020 |
Why?
|
Health Services Research | 1 | 2017 | 1832 | 0.020 |
Why?
|
Greece | 1 | 2010 | 343 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2013 | 881 | 0.020 |
Why?
|
Chaperonin 60 | 1 | 2009 | 103 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 2009 | 330 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 664 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2851 | 0.020 |
Why?
|
Adiponectin | 1 | 2014 | 1096 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6722 | 0.020 |
Why?
|
Apolipoproteins E | 1 | 2013 | 1437 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3514 | 0.020 |
Why?
|
Obesity | 1 | 2009 | 12643 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2016 | 2100 | 0.020 |
Why?
|
Suramin | 1 | 2006 | 34 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2010 | 324 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6237 | 0.020 |
Why?
|
Leptin | 1 | 2014 | 1589 | 0.020 |
Why?
|
Vincristine | 1 | 2008 | 1038 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12237 | 0.020 |
Why?
|
Tubulin | 1 | 2009 | 696 | 0.020 |
Why?
|
Bone Density | 1 | 2018 | 3471 | 0.020 |
Why?
|
Glycoproteins | 1 | 2013 | 2259 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9122 | 0.020 |
Why?
|
Fatigue | 1 | 2011 | 1524 | 0.020 |
Why?
|
Fever | 1 | 2011 | 1607 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2014 | 3194 | 0.010 |
Why?
|
Headache | 1 | 2011 | 1199 | 0.010 |
Why?
|
Prednisone | 1 | 2008 | 1560 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10534 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18349 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15511 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2010 | 2897 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2008 | 2238 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12178 | 0.010 |
Why?
|
Doxorubicin | 1 | 2008 | 2218 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8039 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2014 | 3858 | 0.010 |
Why?
|
Proteomics | 1 | 2013 | 3584 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2008 | 1311 | 0.010 |
Why?
|
Mitomycin | 1 | 2000 | 259 | 0.010 |
Why?
|
Bleomycin | 1 | 2000 | 496 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 20913 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2000 | 13635 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2010 | 10961 | 0.010 |
Why?
|
Fluorouracil | 1 | 2000 | 1609 | 0.010 |
Why?
|
Antifungal Agents | 1 | 1999 | 722 | 0.010 |
Why?
|
Cisplatin | 1 | 2000 | 1617 | 0.010 |
Why?
|
Smoking | 1 | 2010 | 8960 | 0.010 |
Why?
|
Animals | 1 | 2017 | 168368 | 0.000 |
Why?
|